MedTrace Logo

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

NCT06754644 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 808

Last updated 2025-06-10

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the efficacy similarities between QL2107 and Keytruda in metastatic non-squamous NSCLC.

Conditions

Interventions

DRUG

QL2107

200mg on day 1 of each 21-day cycle of the study

DRUG

Pemetrexed

500 mg/m2 on Day 1 of each 21-day cycle of the study

DRUG

Carboplatin

Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles

DRUG

Keytruda®

200mg on day 1 of each 21-day cycle of the study

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06754644 on ClinicalTrials.gov